The BusinessWeek 50 Ranking
9
Amgen
AMGEN MAY BE ONE of the grandpas of the biotech industry, but it’s looking as sprightly as ever. Profits jumped 55% last year on strong sales of its flagship drugs to treat anemia and to prevent chemotherapyinduced infections. Unlike many of its Big Pharma cousins, the California company is adept at balancing its investments in marketing and research, allowing it to boost sales of existing drugs while developing promising new treatments, such as those for colon cancer and osteoporosis. Will Amgen’s constitution stay strong? Analysts predict a 15% annual rate of growth in earnings over the next five years.
Company Info |
|
| 2005 Rank | 106 |
| GET MORE COMPANY INFO | AMGN |
| Market Value $ Million | 92,387.5 |
| Total Return $ Million | (1-yr.) 22.5
(3-yr.) 38.1 |
| 2005 Sales $ Billion | 12.4 |
| Sales Growth $ Million | (1-yr.) 18
(3-yr.) 30.6 |
| Long-Term Growth Est. % | 15.0 |
| Net income $ Million | 3,674.0 |
| Net Income Growth $ Million | (1-yr.) 55
(3-yr.) 27.5 |
| Net Margin %* | 29.6 |
| Return on Inv. Capital (%)* | 16.2 |
| Share Price 12-Mo. Hi/Lo | 87/56 |
| P/E Ratio | 26 |
| Industry | Pharmaceuticals & Biotechnology |
| CORPORATE WEB SITE | |
